Preclinical Development of a Stabilized RH5 Virus-Like Particle Vaccine that Induces Improved Anti-Malarial Antibodies
Author:
King Lloyd D. W., Pulido David, Barrett Jordan R.ORCID, Davies Hannah, Quinkert Doris, Lias Amelia M., Silk Sarah E., Pattinson David J., Diouf Ababacar, Williams Barnabas G., McHugh KirstyORCID, Rodrigues Ana, Rigby Cassandra A., Strazza Veronica, Suurbaar Jonathan, Rees-Spear Chloe, Dabbs Rebecca A., Ishizuka Andrew S., Zhou Yu, Gupta Gaurav, Jin Jing, Li Yuanyuan, Carnrot Cecilia, Minassian Angela M.ORCID, Campeotto IvanORCID, Fleishman Sarel J.ORCID, Noe Amy R., MacGill Randall S., King C. Richter, Birkett Ashley J., Soisson Lorraine A., Long Carole A., Miura Kazutoyo, Ashfield Rebecca, Skinner Katherine, Howarth MarkORCID, Biswas SumiORCID, Draper Simon J.ORCID
Abstract
AbstractThe development of a highly effective vaccine against the pathogenic blood-stage infection of human malaria will require a delivery platform that can induce an antibody response of both maximal quantity and functional quality. One strategy to achieve this includes presenting antigens to the immune system on virus-like particles (VLPs). Here we sought to improve the design and delivery of the blood-stagePlasmodium falciparumreticulocyte-binding protein homolog 5 (RH5) antigen, which is currently in a Phase 2 clinical trial as a full-length soluble protein-in-adjuvant vaccine candidate called RH5.1/Matrix-M™. We identify disordered regions of the full-length RH5 molecule induce non-growth inhibitory antibodies in human vaccinees, and a re-engineered and stabilized immunogen that includes just the alpha-helical core of RH5 induces a qualitatively superior growth-inhibitory antibody response in rats vaccinated with this protein formulated in Matrix-M™ adjuvant. In parallel, bioconjugation of this new immunogen, termed “RH5.2”, to hepatitis B surface antigen VLPs using the “plug-and-display” SpyTag-SpyCatcher platform technology also enabled superior quantitative antibody immunogenicity over soluble antigen/adjuvant in vaccinated mice and rats. These studies identify a new blood-stage malaria vaccine candidate that may improve upon the current leading soluble protein vaccine candidate RH5.1/Matrix-M™. The RH5.2-VLP/Matrix-M™ vaccine candidate is now under evaluation in Phase 1a/b clinical trials.
Publisher
Cold Spring Harbor Laboratory
Reference53 articles.
1. World Health Organization. World Malaria Report, (2022). 2. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial 3. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial 4. Dicko, A. , Ouedraogo, J.B. , Zongo, I. , Sagara, I. , Cairns, M. , Yerbanga, R.S. , Issiaka, D. , Zoungrana, C. , Sidibe, Y. , Tapily, A. , et al. (2023). Seasonal vaccination with RTS,S/AS01(E) vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial. Lancet Infect Dis. 5. Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention;N Engl J Med,2021
|
|